Form 8-K ALNYLAM PHARMACEUTICALS, For: Nov 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at BMO Capital
November 8, 2018 8:56 AM ESTBMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $124.00) while maintaining a Outperform rating.
Kim commented, "We lower our estimates and target price to $116 from $124, following 3Q18 earnings that saw modest initial Onpattro sales... More
